2023 ASH ABSTRACTS

Title: Real-World Evidence in the United States (US) of the Impact of Bridging Therapy Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Status: Oral
Time/Session: 9:30 AM - 11:00 AM, Session: 705
Presenter: Michael Cook

Title: The Composite Health Risk Assessment Model (CHARM) to Predict 1-Year Non-Relapse Mortality (NRM) Among Older Recipients of Allogeneic Transplantation: A Prospective BMT CTN Study 1704

Status: Oral
Time/Session: 9:30 AM - 11:00 AM, Session: 721
Presenter: Andrew Artz

Title: Multicenter, Real-World Study in Patients With R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (Liso-cel) in the United States (US)

Status: Oral
Time/Session: 9:45 AM, Session: 705
Presenter: Jennifer Crombie

Title: Rabbit Antithymocyte (rATG) Exposure and Outcomes After Hematopoietic Cell Transplantation: A Real-World Experience From BMT CTN 1202

Status: Oral
Time/Session: 10:00 AM, Session: 721
Presenter: Madhavi Lakkaraja

Title: Multicenter, Real-World Study in Patients With R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (Liso-cel) in the United States (US)

Status: Oral
Time/Session: 9:30 AM - 11:00 AM, Session: 705
Presenter: Jennifer Crombie

Title: Rabbit Antithymocyte (rATG) Exposure and Outcomes After Hematopoietic Cell Transplantation: A Real-World Experience From BMT CTN 1202

Status: Oral
Time/Session: 9:30 AM - 11:00 AM, Session: 721
Presenter: Madhavi Lakkaraja

Title: Long-Term Outcomes After Unrelated Marrow Transplantation for Aplastic Anemia With Optimized Cyclophosphamide Dose (BMT CTN 0301)

Status: Oral
Time/Session: 2:00 PM - 3:30 PM, Session: 723
Presenter: Mary Eapen

Title: Age-Related Differences in Utilization of Allogeneic HCT for Acute Myeloid Leukemia in California: Results of a Population-Based, Novel Linked Dataset

Status: Oral
Time/Session: 2:00 PM - 3:30 PM, Session: 703
Presenter: Christa Meyer

Title: Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients With Large-B-Cell Lymphoma and Their Impact on Survival

Status: Oral
Time/Session: 4:00 PM - 5:30 PM, Session: 705
Presenter: Roni Shouval

Title: Impact of Publicly Reported Center-Specific Analysis on Patient Selection Practices for Hematopoietic Stem Cell Transplantation

Status: Oral
Time/Session: 4:00 PM - 5:30 PM, Session: 705
Presenter: Christopher Strouse

Title: Donor Hematopoietic Cell Telomere Length and Magnitude of Post-HCT Shortening Predict Survival in Early Stage Leukemia and Myelodysplastic Syndrome

Status: Oral
Time/Session: 4:00 PM - 5:30 PM, Session: 704
Presenter: Shahinaz Gadalla

Title: Factors Associated With Treatment Receipt in Medicare Beneficiaries Diagnosed With Acute Myeloid Leukemia

Status: Oral
Time/Session: 4:00 PM - 5:30 PM, Session: 705
Presenter: Jaime Preussler

Title: Comparative Effectiveness of Axicabtagene Ciloleucel vs Historical Standard-of-Care in Patients With Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Status: Poster
Time/Session: 5:30 to 7:30 pm, Session: 705
Presenter: Swetha Kambham-pati

Title: HLA-DRB1 HED Is Associated With Improved Survival and Decreased Relapse in Patients With Hematologic Malignancies Following Allogeneic Hematopoietic Stem Cell Transplant

Status: Poster
Time/Session: 5:30 PM - 7:30 PM, Session: 732
Presenter: Christine Camacho-Bydum

Title: Monoallelic Pathogenic Variants in Hemophagocytic Lymphohistiocytosis Genes Are Uncommon and not Associated With Hematopoietic Cell Transplantation Outcomes in Severe Aplastic Anemia

Status: Poster
Time/Session: 5:30 PM - 7:30 PM, Session: 723
Presenter: Maryam Rafati

Title: Caregiver Perspectives on Housing, Finances and Employment Post-Allogeneic Hematopoietic Cell Transplant

Status: Poster
Time/Session: 5:30 PM - 7:30 PM, Session: 705
Presenter: Jaime Preussler

Title: Comparative Effectiveness of Axicabtagene Ciloleucel vs Historical Standard-of-Care in Patients With Relapsed or Refractory Follicular Lymphoma: An Analysis of CIBMTR and SCHOLAR-5 Data

Status: Poster
Time/Session: 5:30 to 7:30 pm, Session: 705
Presenter: Swetha Kambham-pati

Title: HLA-DRB1 HED Is Associated With Improved Survival and Decreased Relapse in Patients With Hematologic Malignancies Following Allogeneic Hematopoietic Stem Cell Transplant

Status: Poster
Time/Session: 5:30 PM - 7:30 PM, Session: 732
Presenter: Christine Camacho-Bydum

Title: Monoallelic Pathogenic Variants in Hemophagocytic Lymphohistiocytosis Genes Are Uncommon and not Associated With Hematopoietic Cell Transplantation Outcomes in Severe Aplastic Anemia

Status: Poster
Time/Session: 5:30 PM - 7:30 PM, Session: 723
Presenter: Maryam Rafati

Title: Caregiver Perspectives on Housing, Finances and Employment Post-Allogeneic Hematopoietic Cell Transplant

Status: Poster
Time/Session: 5:30 PM - 7:30 PM, Session: 705
Presenter: Jaime Preussler

ASH ABSTRACTS: Saturday, December 9, 2023

ASH ABSTRACTS: Sunday, December 10, 2023
... continued from previous page

ASH ABSTRACTS: Monday, December 11, 2023

<table>
<thead>
<tr>
<th>Title</th>
<th>Status</th>
<th>Time</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brubinib Added to Standard Conditioning and as Consolidation Therapy Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Primary Analysis of the US Intergroup Double-Bind Randomized Phase III Study Alliance A051301/BMT CTN 1201</td>
<td>Oral</td>
<td>9:30 AM - 11:00 AM Presentation: 10:30 AM Session: 626</td>
<td>Charalampos Andreassis</td>
</tr>
<tr>
<td>Machine Learning Validates Risk Biomarkers of Chronic Graft-Versus-Host Disease in 936 Patients From BMT CTN 0201 &amp; 1202 Cohorts</td>
<td>Oral</td>
<td>9:30 AM - 11:00 AM Presentation: 10:30 AM Session: 722</td>
<td>Michael Martens</td>
</tr>
<tr>
<td>Chimeric Antigen Receptor (CAR) T Cell Infusion for Large B-Cell Lymphoma in Complete Remission: A Center for International Blood &amp; Marrow Transplant Research (CIBMTR) Analysis</td>
<td>Oral</td>
<td>4:30 PM - 6:00 PM Presentation: 5:00 PM Session: 627</td>
<td>Trent Wang</td>
</tr>
<tr>
<td>Persistence of FLT3-TKD in Blood Prior to Allogeneic Transplant Is Associated With Increased Relapse and Death in Adults With AML in First Remission</td>
<td>Poster</td>
<td>6:00 PM - 8:00 PM Session: 617</td>
<td>Pranay S. Hegde</td>
</tr>
<tr>
<td>Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years With Relapsed/Refractory Large B-Cell Lymphoma Treated With Tisagenlecleucel in the Real-World Setting</td>
<td>Poster</td>
<td>6:00 PM - 8:00 PM Session: 705</td>
<td>Daniel Landsburg</td>
</tr>
<tr>
<td>Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood &amp; Marrow Transplant Research (CIBMTR) Analysis</td>
<td>Poster</td>
<td>6:00 PM - 8:00 PM Session: 705</td>
<td>Mazyar Shadman</td>
</tr>
<tr>
<td>Is the Youngest Donor Always the Best Choice to Optimize Outcomes for Matched Unrelated Allogeneic Transplantation? Improving Precision Using Novel Statistical Methodology</td>
<td>Poster</td>
<td>6:00 PM - 8:00 PM Session: 722</td>
<td>Stephen Spellman</td>
</tr>
</tbody>
</table>

ASH ABSTRACTS: Tuesday, December 12, 2023

<table>
<thead>
<tr>
<th>Title</th>
<th>Status</th>
<th>Time/Session</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduced-Intensity Haploidentical Bone Marrow Transplantation in Adults With Severe Sickle Cell Disease: BMT CTN 1507</td>
<td>Oral</td>
<td>9:00 AM - 10:30 AM Presentation: LBA-4 Session: LBA</td>
<td>Adetola Kasim</td>
</tr>
</tbody>
</table>